Evidence map›Paper›PMID 42035135›Full record

ArticleJournal of translational medicine2026

METTL3-mediated m

Shuangming Lin, Hao Zeng, Xueyi Xue, Baodong Liao, Hao Lin, Yuhui Wang, Dongbo Xu

Abstract read
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shuangming Lin *Department of Gastrointestinal and Anal Surgery, Fujian Medical University Affiliated Longyan First Hospital, Longyan, Fujian, 364000, China.
Hao Zeng *Department of Colorectal Surgery, Fujian Medical University Union Hospital,, Fuzhou, China.
Xueyi XueDepartment of Gastrointestinal and Anal Surgery, Fujian Medical University Affiliated Longyan First Hospital, Longyan, Fujian, 364000, China.
Baodong LiaoDepartment of Gastrointestinal and Anal Surgery, Fujian Medical University Affiliated Longyan First Hospital, Longyan, Fujian, 364000, China.
Hao LinDepartment of Gastrointestinal and Anal Surgery, Fujian Medical University Affiliated Longyan First Hospital, Longyan, Fujian, 364000, China.
Yuhui WangDepartment of Gastrointestinal and Anal Surgery, Fujian Medical University Affiliated Longyan First Hospital, Longyan, Fujian, 364000, China.
Dongbo XuDepartment of Gastrointestinal and Anal Surgery, Fujian Medical University Affiliated Longyan First Hospital, Longyan, Fujian, 364000, China. xdb2292388@sina.com.ORCID 0000-0002-6509-9123

Funding

2022LYF17094 FLY2021LYF17042Lanyan City Joint Funding 2022LYF17094Longyan Clinical Medical Research Center of Digestive Diseases 2025LYF1002Natural Science Foundation of Fujian Province 2021J011442
6 · The paper itself

Abstract

backgroundColorectal cancer (CRC), a prevalent malignancy of the digestive system, is often characterized by poor patient prognosis due to high rates of recurrence and metastasis. N6-methyladenosine (m

methodsWe first integrated bioinformatic analysis data, which revealed a significant positive correlation and co-enrichment of methyltransferase-Like 3 (METTL3) and the lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in a high-risk prognostic signature. Functional validation included in vitro assessments of cellular proliferation, migration, invasion, apoptosis, and m

resultsMETTL3 and MALAT1 were markedly upregulated in CRC tissues and cell lines. Molecular docking identified trihydroxy methylcyclohexane aminoglycoside (TMA) as a high-affinity METTL3-binding compound. Inhibition of METTL3 or MALAT1 significantly impaired cellular proliferation, migration, and invasion, while promoting apoptosis. RNA immunoprecipitation quantitative PCR (RIP-qPCR) and RNA stability assays established that METTL3 maintains MALAT1 stability via m

conclusionsCollectively, our work elucidates the METTL3-m

Indexed as

AdenosineColorectal NeoplasmsDisease ProgressionMethyltransferasesNF-kappa BRNA, Long NoncodingSignal TransductionAnimalsApoptosisCell Line, TumorCell MovementCell ProliferationEpitranscriptomeFemaleGene Expression Regulation, NeoplasticHumansAdenosineMALAT1 long non-coding RNA, humanMethyltransferasesMETTL3 protein, humanNF-kappa BN-methyladenosineRNA, Long NoncodingColorectal cancerm6A modificationMALAT1METTL3NF-κB signaling pathway

Identifiers

PMID42035135
PMCPMC13255404

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.